Understand the source comparison
KPV Studied Autoimmune Research: Mechanism Comparison
KPV Peptide Intracellular NF-kappaB inhibition via p65 binding. Blocks pro-inflammatory gene transcription without receptor engagement Low. Preserves T-cell and B-cell surveillance function; no increased infection rates in preclinical models High. Targets TNF-
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV Peptide
- Intracellular NF-kappaB inhibition via p65 binding. Blocks pro-inflammatory gene transcription without receptor engagement
- Low. Preserves T-cell and B-cell surveillance function; no increased infection rates in preclinical models
- High. Targets TNF-alpha, IL-1beta, IL-6 transcription; spares STAT3 and AP-1 pathways
- 2–4 weeks (oral IBD formulations); 3–7 days (subcutaneous dosing)
- Best-suited for cytokine-driven conditions (IBD, contact dermatitis) where NF-kappaB is the dominant inflammatory driver. Less effective in antibody-mediated autoimmunity
- Anti-TNF Biologics (infliximab, adalimumab)
- Monoclonal antibody binds circulating TNF-alpha, preventing receptor engagement and downstream signaling
- Moderate-to-high. Increases risk of tuberculosis reactivation, fungal infections, and malignancy
- Low. Broad TNF blockade affects innate immunity, wound healing, and granuloma formation
- 2–8 weeks (varies by formulation and disease)
- Gold standard for moderate-to-severe RA and IBD but requires infection screening and long-term monitoring; KPV studied autoimmune research suggests complementary rather than replacement role
- Corticosteroids (prednisone, methylprednisolone)
- Binds glucocorticoid receptors, upregulates anti-inflammatory genes and suppresses NF-kappaB, AP-1, and NFAT pathways
- High. Dose-dependent; prolonged use (>2 weeks) suppresses HPA axis and increases infection susceptibility
- Very low. Indiscriminate suppression across immune and metabolic pathways
- 1–3 days (rapid onset)
- Most potent anti-inflammatory but side-effect profile limits long-term use; KPV offers mechanistic overlap (NF-kappaB inhibition) without glucocorticoid receptor agonism
- JAK Inhibitors (tofacitinib, baricitinib)
- Small-molecule inhibition of Janus kinase enzymes, blocking STAT-mediated cytokine signaling (IL-6, IL-12, IL-23, interferons)
- Moderate. Increases herpes zoster reactivation and opportunistic infections; thrombosis risk with tofacitinib
- Moderate. Targets JAK-STAT pathways but spares NF-kappaB-dependent cytokines like TNF-alpha
- 2–4 weeks
- Effective for RA and UC refractory to biologics; mechanistically distinct from KPV, suggesting potential combination approaches in research settings
- Methotrexate
- Inhibits dihydrofolate reductase, reducing purine synthesis and T-cell proliferation; weak NF-kappaB inhibition at high doses
- Low-to-moderate. Myelosuppression risk with prolonged use; folic acid supplementation mitigates most toxicity
- Low. Primarily antiproliferative rather than cytokine-specific
- 4–8 weeks (slow onset)
- Standard DMARD for RA; KPV studied autoimmune research shows faster onset but lacks methotrexate's proven long-term joint protection